Last reviewed · How we verify
Lamotrigine ER tablet 50mg — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Lamotrigine ER tablet 50mg (Lamotrigine ER tablet 50mg) — Alembic Pharmaceuticals Ltd..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Lamotrigine ER tablet 50mg TARGET | Lamotrigine ER tablet 50mg | Alembic Pharmaceuticals Ltd. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Lamotrigine ER tablet 50mg CI watch — RSS
- Lamotrigine ER tablet 50mg CI watch — Atom
- Lamotrigine ER tablet 50mg CI watch — JSON
- Lamotrigine ER tablet 50mg alone — RSS
Cite this brief
Drug Landscape (2026). Lamotrigine ER tablet 50mg — Competitive Intelligence Brief. https://druglandscape.com/ci/lamotrigine-er-tablet-50mg. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab